The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

Icagen Issued US Patent

16-May-2016 | Source : Icagen | Visits : 6626
DURHAM, N.C. - Icagen Inc. today announced in a press release that the US Patent and Trademark Office has granted the company patent number 9,335,284 B2, “Methods for Analysis Using X-Ray Fluorescence,” covering applications of the company’s proprietary XRpro® X-ray fluorescence technology to the development of biomarkers and diagnostics. The company also said the USPTO had granted Notices of Allowance for two further patent applications covering the XRpro technology’s use in such applications, Nos. 14/715,218 and 14/715,206. The term of coverage for each of the three patents extends to 2031. 

“Icagen’s XRpro platform makes this powerful method of molecular analysis via x-ray spectroscopy useful for examining important questions in biology. Many of these questions are relevant to the development and use of therapeutics and molecular diagnostics for significant medical needs, such as cancer,” said Doug Krafte, Ph.D., Icagen Chief Scientific Officer. “The unique aspect of this patent is the application of x-ray spectroscopy, long used for analytical purposes in materials science, to expand the elemental analysis of biological and clinical samples.

While many approaches to elemental analysis in biology are capable of analyzing specific elements, we can simultaneously analyze a large fraction of the periodic table using the methods covered in these patents. We anticipate that this will allow us to identify unique markers of human disease progression as well as potentially allow Icagen to identify novel therapeutic targets for our partners’ efforts to discover and develop next-generation drugs.” 

Related Articles